medigraphic.com
ISSN 0035-0052 (Print)

2022, Number 5

<< Back Next >>

Rev Mex Pediatr 2022; 89 (5)

Factors related to the honeymoon period in pediatric patients with type 1 diabetes mellitus during the first year of diagnosis

Márquez-Sainz NA, Bernárdez-Zapata I, Antillón-Ferreira C, Escobedo-Berumen L, Sánchez-Rodríguez A

Language: Spanish
References: 28
Page: 184-189
PDF size: 242.47 Kb.


ABSTRACT

Introduction: in type 1 diabetes mellitus (DM1) there is autoimmune destruction of pancreatic β cells with metabolic decompensation. In the first months of starting treatment, a period of partial remission or "honeymoon" may appear, in which there is a decrease in exogenous insulin requirements. Objective: to identify factors associated with partial remission in pediatric patients with DM1, during the first 12 months after diagnosis. Material and methods: retrospective study of a cohort of pediatric patients initially diagnosed with DM1, in a private hospital in Mexico City. We analyzed the clinical characteristics at diagnosis, subsequent management, and the stay in partial remission during the first 12 months after diagnosis. Results: forty-four patients with a median age of nine years were included, 25 were male (56.8%). 70.5% (31/44) presented partial remission at some point during follow-up, but for 12 months only 22 (50%) maintained partial remission. Factors associated with losing partial remission at 12 months were: age less than six years (OR: 6.9, 95% CI 1.06-44.9) and do not perform continuous blood glucose monitoring (OR = 6.7, 95% CI 1.3-34.4). Conclusion: during the first year of treatment, up to 70% of patients with a recent diagnosis of DM1 may have partial remission. Better blood glucose monitoring and being a patient older than six years are associated with partial remission.


REFERENCES

  1. Mortensen HB, Swift PG, Holl RW, Hougaard P, Hansen L, Bjoerndalen H et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes. 2010; 11(4): 218-226.

  2. Wang Y, Gong C, Cao B, Meng X, Wei L, Wu D et al. Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus. Pediatr Diabetes. 2017; 18(3): 196-203.

  3. Kara O, Esen I, Tepe D. Factors influencing frequency and duration of remission in children and adolescents newly diagnosed with type 1 diabetes. Med Sci Monit. 2018; 24: 5996-6001.

  4. Fonolleda M, Murillo M, Vázquez F, Bel J, Vives-Pi M. Remission phase in paediatric type 1 diabetes: new understanding and emerging biomarkers. Horm Res Paediatr. 2017; 88(5): 307-315.

  5. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1998; 128(7): 517-523.

  6. Thrailkill KM, Moreau CS, Swearingen C, Rettiganti M, Edwards K, Morales AE et al. Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes. Diabetes Technol Ther. 2011; 13(10): 1023-1030.

  7. Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009; 32(8): 1384-1390.

  8. Bizzarri C, Benevento D, Ciampalini P, Patera Ippolita P, Schiaffini R, Migliaccio A et al. Clinical presentation and autoimmune characteristics of very young children at the onset of type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010; 23(11): 1151-1157.

  9. Abdul-Rasoul M, Habib H, Al-Khouly M. 'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006; 7(2): 101-107.

  10. Nwosu BU. Partial clinical remission of type 1 diabetes mellitus in children: clinical applications and challenges with its definitions. Eur Med J Diabetes. 2019;4(1): 89-98.

  11. Tang R, Zhong T, Wu C, Zhou Z, Li X. The remission phase in type 1 diabetes: role of hyperglycemia rectification in immune modulation. Front Endocrinol (Lausanne). 2019 Dec; 10: 824.

  12. Zhong T, Tang R, Gong S, Li J, Li X, Zhou Z. The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno-metabolic mechanisms. Diabetes Metab Res Rev. 2020; 36(2): e3207.

  13. Dost A, Herbst A, Kintzel K, Haberland H, Roth CL, Gortner L et al. Shorter remission period in young versus older children with diabetes mellitus type 1. Exp Clin Endocrinol Diabetes. 2007; 115(1): 33-37.

  14. Scholin A, Torn C, Nystrom L, Berne C, Arnqvist H, Blohmé G et al. Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in Type 1 diabetes. Diabet Med. 2004; 21(5): 447-455.

  15. Passanisi S, Salzano G, Gasbarro A, Urzi Brancati V, Mondio M, Pajno GB, et al. Influence of age on partial clinical remission among children with newly diagnosed type 1 diabetes. Int J Environ Res Public Health. 2020; 17(13): 4801.

  16. Marino KR, Lundberg RL, Jasrotia A, Maranda LS, Thompson MJ, Barton BA et al. A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetes. PLoS One. 2017; 12(5): e0176860.

  17. Chobot A, Stompór J, Szyda K, Sokolowska M, Deja G, Polanska J et al. Remission phase in children diagnosed with type 1 diabetes in years 2012 to 2013 in Silesia, Poland: An observational study. Pediatr Diabetes. 2019; 20(3): 286-292.

  18. Nagl K, Hermann JM, Plamper M, Schroder C, Dost A, Kordonouri O et al. Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose-adjusted HbA1c in 3657 children and adolescents from Germany and Austria. Pediatr Diabetes. 2017; 18(6): 428-434.

  19. Pozzilli P, Manfrini S, Buzzetti R, Lampeter E, Leeuw ID, Iafusco D et al. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Res Clin Pract. 2005; 68(3): 258-264.

  20. Lombardo F, Valenzise M, Wasniewska M, Messina MF, Ruggeri C, Arrigo T et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab. 2002; 15(4): 246-251.

  21. Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). Diabetes Metab Res Rev. 1999; 15(3): 181-185.

  22. Bowden SA, Duck MM, Hoffman RP. Young children (<5 yr) and adolescents (>12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes. 2008; 9(3 Pt 1): 197-201.

  23. Bowden SA. Partial remission (honeymoon phase) in type 1 diabetes mellitus. Frontiers in Clinical Drug Research-Diabetes and Obesity. 2021; 7(9): 1-20.

  24. Patton SR, Williams LB, Eder SJ, Crawford MJ, Dolan L, Powers SW. Use of continuous glucose monitoring in young children with type 1 diabetes: implications for behavioral research. Pediatr Diabetes. 2011; 12(1): 18-24.

  25. Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group. A randomized clinical trial assessing continuous glucose monitoring (CGM) use with standardized education with or without a family behavioral intervention compared with fingerstick blood glucose monitoring in very young children with type 1 diabetes. Diabetes Care. 2021; 44(2): 464-472.

  26. Laffel LM, Kanapka LG, Beck RW, Bergamo K, Clements MA, Criego A et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020; 323(23): 2388-2396.

  27. Phillip M, Danne T, Shalitin S, Buckingham B, Laffel L, Tamborlane W et al. Use of continuous glucose monitoring in children and adolescents (1). Pediatr Diabetes. 2012; 13(3): 215-228.

  28. Schloot NC, Hanifi-Moghaddam P, Aabenhus-Andersen N, Alizadeh BZ, Saha MT, Knip M et al. Association of immune mediators at diagnosis of Type 1 diabetes with later clinical remission. Diabet Med. 2007; 24(5): 512-520.




2020     |     www.medigraphic.com